Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

triamcinolone acetonide transdermal system SUN-131

A transdermal system (TDS) containing triamcinolone acetonide, a synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. Upon application of the TDS to the eyelid, triamcinolone acetonide binds to intracellular glucocorticoid receptors, ultimately inducing the expression of glucocorticoid-responsive genes and lipocortins. Lipocortins inhibit phospholipase A2, thereby blocking the release of arachidonic acid from membrane phospholipids and preventing the synthesis of prostaglandins and leukotrienes, both mediators of inflammation. In addition, pro-inflammatory cytokine production, including interleukin (IL)-1and IL-6, and the activation of cytotoxic T lymphocytes is also inhibited. Triamcinolone acetonide also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis through increasing Ikappa-B expression and curtailing activation of nuclear factor (NF)kappa-B.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:SUN-131 TDS
triamcinolone acetonide transdermal patch SUN-131
Code name:SUN 131
SUN-131
SUN131
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search